The number of treatment options for lung adenocarcinoma (ADC) has increased in recent decades following the identification of sensitizing epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements as molecular targets for effective agents [3]. Here, ALK is linked to lung adenocarcinoma.